Stock Performance and Price Movement
The stock of Vivimed Labs (Stock ID: 612893) has experienced a notable slide, dropping by 4.99% on the day to reach ₹11.10, its lowest level in the past year. This decline comes after a continuous 12-day losing streak, during which the stock has shed approximately 53.88% in returns. Despite this recent weakness, the stock price remains above its 50-day, 100-day, and 200-day moving averages, though it is trading below the shorter-term 5-day and 20-day moving averages, indicating near-term selling pressure.
In comparison, the broader market has shown relative resilience. The Sensex, while experiencing a sharp fall of 641.46 points (-0.97%) on the same day, remains just 2.4% shy of its 52-week high of 86,159.02. The index is trading below its 50-day moving average, but the 50DMA itself is positioned above the 200DMA, signalling a mixed technical backdrop for the market overall.
Fundamental Metrics and Financial Health
Vivimed Labs’ current Mojo Score stands at 24.0, with a Mojo Grade of Strong Sell as of 22 Dec 2025, reflecting concerns over the company’s financial and operational standing. This rating marks a downgrade from a previously ungraded status, underscoring deteriorating fundamentals.
The company’s market capitalisation grade is rated at 4, indicating a relatively modest market cap compared to peers. The stock has underperformed significantly over the past year, generating a flat return of 0.00%, while the Sensex has advanced by 7.69% during the same period.
Our current Stock of the Month is out! This Large Cap from Automobiles - Passenger Cars emerged as the single best opportunity from our elite universe. Get the details now!
- - Current monthly selection
- - Single best opportunity
- - Elite universe pick
Profitability and Debt Concerns
One of the key factors weighing on Vivimed Labs is its weak profitability. The company has reported an average Return on Equity (ROE) of just 1.75%, signalling limited earnings generated per unit of shareholders’ funds. This low profitability is compounded by a high debt burden, with a Debt to EBITDA ratio of 12.57 times, indicating significant leverage and potential challenges in servicing debt obligations.
Recent financial disclosures highlight further stress. The half-yearly Profit After Tax (PAT) stood at a loss of ₹281.57 crores, reflecting a decline of 34.93% compared to previous periods. The debt-equity ratio remains elevated at 9.60 times, the highest recorded in recent reporting, while the debtors turnover ratio has dropped to 2.44 times, the lowest level observed, suggesting slower collections and potential liquidity constraints.
Market Risk and Valuation
Vivimed Labs is currently trading at valuations considered risky relative to its historical averages. The absence of financial results for the last six months has contributed to uncertainty around the company’s current performance and outlook. Over the past year, the company’s profits have contracted sharply by 267.9%, underscoring the challenges faced in maintaining earnings momentum.
In the context of the broader market, Vivimed Labs’ performance contrasts with the Sensex’s steady gains, highlighting the stock’s relative underperformance and the pressures it faces within its sector and peer group.
Holding Vivimed Labs from ? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary of Key Financial Indicators
To summarise, Vivimed Labs’ financial profile as of the latest available data includes:
- Mojo Score: 24.0 (Strong Sell)
- Debt to EBITDA Ratio: 12.57 times
- Return on Equity (average): 1.75%
- Half-yearly PAT: ₹-281.57 crores, down 34.93%
- Debt-Equity Ratio (half-yearly): 9.60 times
- Debtors Turnover Ratio (half-yearly): 2.44 times
- One-year profit decline: -267.9%
- One-year stock return: 0.00%
Market Context and Broader Trends
While Vivimed Labs has been under pressure, the broader market environment has been mixed. The Sensex’s recent decline of nearly 1% on 8 Jan 2026 followed a negative opening, but the index remains close to its 52-week high, reflecting underlying market strength. The index’s technical indicators suggest some caution, with the Sensex trading below its 50-day moving average, though the longer-term trend remains intact with the 50DMA above the 200DMA.
Against this backdrop, Vivimed Labs’ stock has diverged significantly, reflecting company-specific factors that have weighed on investor sentiment and valuation.
Conclusion
Vivimed Labs’ fall to a 52-week low of ₹11.10 marks a continuation of a challenging period for the company, characterised by weak profitability, high leverage, and a lack of recent financial disclosures. The stock’s underperformance relative to the broader market and its deteriorating financial metrics highlight the pressures it faces. Investors and market participants will continue to monitor the company’s financial updates and market developments closely as the situation evolves.
Unlock special upgrade rates for a limited period. Start Saving Now →
